Peptides for Inflammation: What the Research Shows
Chronic inflammation sits underneath an enormous range of conditions — from joint and gut problems to metabolic and neurological disease. Several research peptides are studied for their ability to modulate the inflammatory response rather than simply suppress it. This guide breaks down the most-researched options, how each works, and how strong the evidence actually is.
Research context. Every compound below is a research peptide, not an approved anti-inflammatory drug. This article is educational and is not medical advice. Most human evidence is preliminary. Consult a qualified physician before use.
The Most-Studied Peptides for Inflammation
A synthetic fragment of a protein found in gastric juice. Animal models repeatedly show downregulation of pro-inflammatory cytokines (TNF-α, IL-6) and accelerated resolution of inflammation in gut, tendon, and muscle tissue, alongside its better-known angiogenic repair effects.
Evidence: Extensive animal data; strong anecdotal human use for gut and joint inflammation
BPC-157 — Base PeptidesKPV is the C-terminal tripeptide of α-MSH. It enters cells and acts directly on the NF-κB pathway, dampening inflammatory signalling without the pigmentary effects of the full α-MSH molecule. Studied most for inflammatory bowel conditions and inflammatory skin.
Evidence: Preclinical models of colitis and dermatitis; growing research interest
KPV — Base PeptidesRather than blunting the immune system, Tα1 helps re-regulate it — shifting T-cell balance and modulating both over- and under-active immune responses. This makes it a research candidate where chronic inflammation is driven by immune dysregulation.
Evidence: Decades of clinical research (approved in several countries for other indications)
Thymosin Alpha-1 — Base PeptidesTB-500 upregulates actin and promotes cell migration into damaged tissue. Alongside repair, research describes a reduction in inflammation and scar tissue formation, which is why it is frequently paired with BPC-157 in recovery protocols.
Evidence: Animal repair models; widely used anecdotally with BPC-157
TB-500 — Base PeptidesA human cathelicidin peptide with antimicrobial activity and complex immunomodulatory effects. Research interest centres on conditions where infection and chronic inflammation overlap, though its effects are dose- and context-dependent.
Evidence: Active research area; effects are biphasic and context-dependent
LL-37 — Base PeptidesVIP is one of the body's own anti-inflammatory messengers, suppressing pro-inflammatory mediators while promoting regulatory T-cell activity. It is studied in chronic inflammatory and neuroinflammatory research contexts, typically via nasal administration.
Evidence: Endogenous peptide with active inflammatory-disease research
VIP — Base PeptidesConventional anti-inflammatories (NSAIDs, corticosteroids) work by blunting the inflammatory cascade broadly. That is effective short-term but carries trade-offs with long-term use. The research interest in peptides centres on a different idea: re-regulating an over-active response while still allowing the healing functions of inflammation to proceed.
This is why peptides like BPC-157 and TB-500 are studied for situations where inflammation and tissue damage coexist — they appear to reduce excessive inflammation while actively supporting repair, rather than simply switching the signal off.
Start with one compound and a clear target — inflammation is not one disease, and what helps gut inflammation may differ from what helps a joint. Keep notes on the specific area you are tracking.
Source quality matters as much as compound selection. Use a supplier that provides batch-specific third-party certificates of analysis (CoA) confirming purity and identity. Underdosed or contaminated material is common in this market.
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →